Evidence map›Paper›PMID 35751102›Full record

ArticleAlzheimer's research & therapy2022

Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys.

Sasan D Noveir, Bilal E Kerman, Haotian Xian, Cristiana Meuret, Sabrina Smadi, Ashley E Martinez, Johannes Johansson, Henrik Zetterberg, Bryan A Parks, Zsuzsanna Kuklenyik and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. APOE-Targeted Therapeutics for Alzheimer's Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Apolipoprotein E in lipid metabolism and neurodegenerative disease.Trends in endocrinology and metabolism: TEM · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Sasan D NoveirDepartments of Medicine and Neurology, University of Southern California, Los Angeles, CA, 90033, USA.
Bilal E KermanDepartments of Medicine and Neurology, University of Southern California, Los Angeles, CA, 90033, USA.
Haotian XianDepartments of Medicine and Neurology, University of Southern California, Los Angeles, CA, 90033, USA.
Cristiana MeuretDepartments of Medicine and Neurology, University of Southern California, Los Angeles, CA, 90033, USA.
Sabrina SmadiDepartments of Medicine and Neurology, University of Southern California, Los Angeles, CA, 90033, USA.
Ashley E MartinezDepartments of Medicine and Neurology, University of Southern California, Los Angeles, CA, 90033, USA.
Johannes JohanssonArtery Therapeutics, Inc., San Ramon, CA, 94583, USA.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Bryan A ParksCenters for Disease Control and Prevention, Atlanta, GA, 30341, USA.
Zsuzsanna KuklenyikCenters for Disease Control and Prevention, Atlanta, GA, 30341, USA.
Wendy J MackDepartment of Population and Public Health Sciences, University of Southern California, Los Angeles, CA, 90033, USA.
Jan O JohanssonArtery Therapeutics, Inc., San Ramon, CA, 94583, USA. jjohansson@arterytx.com.
Hussein N YassineDepartments of Medicine and Neurology, University of Southern California, Los Angeles, CA, 90033, USA. Hyassine@usc.edu.
University of Southern California · USCenters for Disease Control and Prevention · USNational Hospital for Neurology and Neurosurgery · GB

Funding

VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHUI, HELENA CHANG · 1985 to 2019
$41.0M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Hussein N Yassine · 2020 to 2026
$27.8M
The delivery of essential fatty acids to the Brain in Alzheimer's diseaseR01AG054434 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 2017 to 2021
$5.4M
Biomarkers of ABCA1 mediated functions in Alzheimers diseaseR01AG055770 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 2017 to 2021
$4.2M
ApoE, ABCA1 and endosomal dysregulation in ADR01AG067063 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 2020 to 2024
$3.4M
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253R44AG076299 · NIA · ARTERY THERAPEUTICS, INC. · PI JOHANSSON, JAN · 2021 to 2023
$3.0M
CS6253 development for the treatment of apoE4 driven dementia includingAlzheimer's diseaseR44AG060826 · NIA · ARTERY THERAPEUTICS, INC. · PI JOHANSSON, JAN · 2019 to 2020
$2.9M
Brain cPLA2 as a mechanism for neuroinflammation in AD/ADRD with and without APOE4 Diversity SupplementRF1AG076124 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ARVANITAKIS, ZOE, YASSINE, HUSSEIN N · 2022 to 2024
$2.5M
DHA brain delivery by APOE genotypeR21AG056518 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 2018 to 2019
$464k
NIA NIH HHS P30 AG066530NIA NIH HHS P50 AG005142NIA NIH HHS R01 AG054434NIA NIH HHS R01 AG055770NIA NIH HHS R01 AG067063NIA NIH HHS R21 AG056518NIA NIH HHS R44 AG060826NIA NIH HHS R44AG060826NIA NIH HHS R44 AG076299NIA NIH HHS RF1 AG076124
6 · The paper itself

Abstract

backgroundInducing brain ATP-binding cassette 1 (ABCA1) activity in Alzheimer's disease (AD) mouse models is associated with improvement in AD pathology. The purpose of this study was to investigate the effects of the ABCA1 agonist peptide CS-6253 on amyloid-β peptides (Aβ) and lipoproteins in plasma and cerebrospinal fluid (CSF) of cynomolgus monkeys, a species with amyloid and lipoprotein metabolism similar to humans.

methodsCS-6253 peptide was injected intravenously into cynomolgus monkeys at various doses in three different studies. Plasma and CSF samples were collected at several time points before and after treatment. Levels of cholesterol, triglyceride (TG), lipoprotein particles, apolipoproteins, and Aβ were measured using ELISA, ion-mobility analysis, and asymmetric-flow field-flow fractionation (AF4). The relationship between the change in levels of these biomarkers was analyzed using multiple linear regression models and linear mixed-effects models.

resultsFollowing CS-6253 intravenous injection, within minutes, small plasma high-density lipoprotein (HDL) particles were increased. In two independent experiments, plasma TG, apolipoprotein E (apoE), and Aβ42/40 ratio were transiently increased following CS-6253 intravenous injection. This change was associated with a non-significant decrease in CSF Aβ42. Both plasma total cholesterol and HDL-cholesterol levels were reduced following treatment. AF4 fractionation revealed that CS-6253 treatment displaced apoE from HDL to intermediate-density- and low density-lipoprotein (IDL/LDL)-sized particles in plasma. In contrast to plasma, CS-6253 had no effect on the assessed CSF apolipoproteins or lipids.

conclusionsTreatment with the ABCA1 agonist CS-6253 appears to favor Aβ clearance from the brain.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsApolipoproteinsApolipoproteins EATP Binding Cassette Transporter 1CholesterolHumansMacaca fascicularisMicePeptidesABCA1 protein, humanAbca1 protein, mouseAmyloid beta-PeptidesApolipoproteinsApolipoproteins EATP Binding Cassette Transporter 1CholesterolCS-6253PeptidesABCA1Alzheimer’s diseaseApolipoprotein ECS-6253

Identifiers

PMID35751102
PMCPMC9229758
OpenAlexW4283375554

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.